Type: Poster presentation
Presented by: Trudy J. Rumann Heil
Conference: V International Symposium Interaction of Nervous and Immune Systems in Health and Disease
Location: Institute of Experimental Medicine, St. Petersburg, Russia
Date: June 23-26, 2015
Additional Content: PDF of poster
Treatment of chronic disorders of the nervous and immune systems calls for a new approach, as many patients do not respond to current treatment modalities. Seven years ago, we began to explore a novel immuno-modulating therapy using a retargeted drug, which, when dosed more frequently than usual, stimulates the innate immune system by acting as a VDR nuclear receptor agonist. The drug, olmesartan medoxomil, was provided as a monotherapy to volunteer patients who had previously failed to respond to 'standard of care'.
Sixty two (62) volunteer patients from a private practice in Arizona were admitted as participants in this observational cohort. Emotional support was offered to assist in subject retention, using collaboration on an Internet discussion site and in-person local support meetings (a participatory model of health-care). Conventional clinical symptoms were monitored between 2008 and 2012, using 'The Symptom Profile' tool at each encounter. Other symptoms presented here, including insomnia, depression, fatigue, irritability, and loss of focus, were self-reported. The wide range of diagnoses which responded well to this immunostimulative therapy were neurologic (depression, anxiety, fatigue, insomnia, migraine, CFS), autoimmuneA condition or disease thought to arise from an overactive immune response of the body against substances and tissues normally present in the body (sarcoidosis, lupus erythematosus, Hashimoto’s, rheumatoid arthritis, CFS), hormonal (pre-menstrual syndrome, polycystic ovary syndrome, metabolic syndrome, insulin resistance), and musculo-skeletal (osteoarthritis, osteopenia, fibromyalgia, CFS). Case-series data will be presented, with case details available upon request.